Effectiveness and safety of dydrogesterone versus dienogest after laparoscopic cystectomy for ovarian endometrioma: a multicenter prospective cohort study

Abstract Background Prospective evidence to guide the choice between dydrogesterone and dienogest after laparoscopic cystectomy for ovarian endometrioma remains limited. This study compared their effectiveness and safety in women of reproductive age to inform individualized postoperative treatment. Methods This prospective multicenter cohort enrolled women aged 18–45 years who underwent laparoscopic cystectomy for histologically confirmed ovarian endometrioma at four hospitals in Guangdong Province, China. Patients and clinicians jointly selected postoperative therapy with either dydrogesterone (10 mg twice daily on cycle days 5–25) or continuous dienogest (2 mg daily) during routine care. The primary outcome was the change in visual analog scale (VAS) pain score from preoperative baseline to week 24. Between-group differences were estimated using covariate-adjusted analysis of covariance with HC3 robust standard errors. The study was registered at ClinicalTrials.gov (NCT05976529) on 25 April 2023. Results A total of 242 women were enrolled: 109 initiated dydrogesterone and 133 initiated dienogest; 234 (96.7%) had VAS data available at week 24. The adjusted between-group difference in VAS pain score change was 0.00 points (95% CI, − 0.44 to 0.43; P = 0.983; dydrogesterone minus dienogest), and estimates were similar across sensitivity analyses. At week 24, the improvement in the Mental Component Summary score of the 12-Item Short Form Health Survey was greater with dydrogesterone (adjusted mean difference, 5.32 points; 95% CI, 2.28 to 8.35; Benjamini-Hochberg [BH]-adjusted P = 0.004). Cyclic bleeding was the predominant bleeding pattern in the dydrogesterone group, whereas no bleeding was the predominant pattern in the dienogest group. Through week 24, any adverse event was reported in 38.1% of the dydrogesterone group versus 54.3% of the dienogest group (BH-adjusted P = 0.063); anxiety or depression (5.7% vs 22.5%; BH-adjusted P = 0.009) and insomnia (4.8% vs 17.8%; BH-adjusted P = 0.018) were reported less frequently with dydrogesterone than with dienogest. Conclusions After adjustment, the improvement in VAS pain score at 24 weeks did not differ significantly between dydrogesterone and dienogest. Differences in mental well-being, adverse events, and bleeding patterns may help guide individualized postoperative treatment decisions.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-11504446/v1
Primary Topic
Endometriosis Research and Treatment
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Effectiveness and safety of dydrogesterone versus dienogest after laparoscopic cystectomy for ovarian endometrioma: a multicenter prospective cohort study

Xiaowan Luo, Wenjing Lu, Huazhang Miao, Xinke Zhao et al.
Research Square
Endometriosis Research and Treatment
preprint

Effectiveness and safety of dydrogesterone versus dienogest after laparoscopic cystectomy for ovarian endometrioma: a multicenter prospective cohort study

Xiaowan Luo, Wenjing Lu, Huazhang Miao, Xinke Zhao, Li Li, Mingshan Zhu, Jiao Liu
preprint en

Abstract

Abstract Background Prospective evidence to guide the choice between dydrogesterone and dienogest after laparoscopic cystectomy for ovarian endometrioma remains limited. This study compared their effectiveness and safety in women of reproductive age to inform individualized postoperative treatment. Methods This prospective multicenter cohort enrolled women aged 18–45 years who underwent laparoscopic cystectomy for histologically confirmed ovarian endometrioma at four hospitals in Guangdong Province, China. Patients and clinicians jointly selected postoperative therapy with either dydrogesterone (10 mg twice daily on cycle days 5–25) or continuous dienogest (2 mg daily) during routine care. The primary outcome was the change in visual analog scale (VAS) pain score from preoperative baseline to week 24. Between-group differences were estimated using covariate-adjusted analysis of covariance with HC3 robust standard errors. The study was registered at ClinicalTrials.gov (NCT05976529) on 25 April 2023. Results A total of 242 women were enrolled: 109 initiated dydrogesterone and 133 initiated dienogest; 234 (96.7%) had VAS data available at week 24. The adjusted between-group difference in VAS pain score change was 0.00 points (95% CI, − 0.44 to 0.43; P = 0.983; dydrogesterone minus dienogest), and estimates were similar across sensitivity analyses. At week 24, the improvement in the Mental Component Summary score of the 12-Item Short Form Health Survey was greater with dydrogesterone (adjusted mean difference, 5.32 points; 95% CI, 2.28 to 8.35; Benjamini-Hochberg [BH]-adjusted P = 0.004). Cyclic bleeding was the predominant bleeding pattern in the dydrogesterone group, whereas no bleeding was the predominant pattern in the dienogest group. Through week 24, any adverse event was reported in 38.1% of the dydrogesterone group versus 54.3% of the dienogest group (BH-adjusted P = 0.063); anxiety or depression (5.7% vs 22.5%; BH-adjusted P = 0.009) and insomnia (4.8% vs 17.8%; BH-adjusted P = 0.018) were reported less frequently with dydrogesterone than with dienogest. Conclusions After adjustment, the improvement in VAS pain score at 24 weeks did not differ significantly between dydrogesterone and dienogest. Differences in mental well-being, adverse events, and bleeding patterns may help guide individualized postoperative treatment decisions.

Research Square
Longgang Central Hospital (CN), First People's Hospital of Foshan (CN), Boai Hospital of Zhongshan (CN), Guangdong Province Women and Children Hospital (CN)
Natural Science Foundation of Guangdong Province, Guangdong Science and Technology Department
Good health and well-being
Endometriosis Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon